Therapy for advanced non-small-cell lung cancer has developed significantly with new
awareness of histologic subtype as an important factor in guiding treatment and the …

Lung cancer has become the leading cause of cancer deaths, with nonsmall cell lung
cancer (NSCLC) accounting for around 80% of lung cancer cases. Chemotherapy is the …

Purpose: Racotumomab-alum is an anti-idiotype vaccine targeting the NeuGcGM3 tumor-
associated ganglioside. This clinical trial was conducted to provide a preliminary estimate of …

Abstract Introduction: In Cuba, lung cancer represents the first cause of mortality for both
sexes. Non-small cell lung cancer (NSCLC) is the most prevalent histology. Overall, 75-85 …

Background: Chinese Herb Medicine Formulas (CHMF) was reported to improve the quality
of life (QoL) in advanced NSCLC patients. The present study was designed to investigate …

Introduction: Non-small cell lung cancer (NSCLC) remains one of the big cancer killers,
despite the introduction of a number of approved therapeutics in recent times. Pemetrexed is …

Background The BEYOND trial found that the addition of bevacizumab (B) to paclitaxel–
carboplatin (PC) chemotherapy provided a significant clinical benefit to Chinese patients …

Introduction: Non-small cell lung cancer (NSCLC) is a major cause of cancer-related death
worldwide. Although advanced NSCLC is still incurable, various anti-neoplastic agents have …

A potential therapeutic strategy for patients who respond (or have stable disease) on a fixed-
duration induction therapy is to receive maintenance therapy, typically given for a prolonged …

Background Recent trials have suggested that maintenance treatments improve outcomes
for patients not progressing after first-line therapy for advanced non-small-cell lung cancer …